Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

Abstract Background Fremanezumab has demonstrated to be effective, safe, and tolerated in the prevention of episodic or chronic migraine (CM) in randomized, placebo-controlled trials (RCTs). Real-life studies are needed to explore drug effects in unselected patients in routine circumstances and to p...

Full description

Bibliographic Details
Published in:	The Journal of Headache and Pain
Main Authors:	Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo FilippiBonassi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi, Fabrizio Vernieri, for the FRIEND-Study Group
Format:	Article
Language:	English
Published:	BMC 2022-04-01
Subjects:	Fremanezumab Migraine treatment CGRP monoclonal antibody Real-world Predictor
Online Access:	https://doi.org/10.1186/s10194-022-01396-x

Similar Items

Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
by: Piero Barbanti, et al.
Published: (2023-03-01)

Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
by: Piero Barbanti, et al.
Published: (2024-03-01)

Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
by: Piero Barbanti, et al.
Published: (2022-06-01)

Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
by: Piero Barbanti, et al.
Published: (2022-04-01)

An Evidence-Based Review of Fremanezumab for the Treatment of Migraine
by: Ivan Urits, et al.
Published: (2020-03-01)

Efficacy of fremanezumab in patients with chronic migraine and concomitant depression
by: A.Y. Timokhovich, et al.
Published: (2024-10-01)

Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine—A Real-Life Study
by: Magdalena Nowaczewska, et al.
Published: (2022-05-01)

Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response
by: Dawn C. Buse, et al.
Published: (2024-03-01)

Safety and efficacy of fremanezumab in real clinical practice in patients with chronic migraine
by: G. N. Belskaya, et al.
Published: (2024-02-01)

Glycerol Trinitrate Acts Downstream of Calcitonin Gene-Related Peptide in Trigeminal Nociception—Evidence from Rodent Experiments with Anti-CGRP Antibody Fremanezumab
by: Nicola Benedicter, et al.
Published: (2024-03-01)

Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE—The First Italian Multicenter, Prospective, Real-Life Study
by: Piero Barbanti, et al.
Published: (2024-06-01)

A National Cross-Sectional Survey on Real-World Experiences of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody Use in Adults with Migraine in Finland
by: Caroline S. Casey, et al.
Published: (2025-04-01)

The Management of High-Frequency Episodic and Chronic Migraines with Calcitonin Gene-Related Peptide Monoclonal Antibody
by: Larisa A. Dobrynina, et al.
Published: (2023-06-01)

Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study
by: Seiya Ohtani, et al.
Published: (2023-11-01)

Efficacy of anti-calcitonin gene-related peptide monoclonal antibodies in hemiplegic migraine: a case report and review of literature
by: Máté Héja, et al.
Published: (2025-04-01)

The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow
by: Mária Dux, et al.
Published: (2022-05-01)

Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
by: Davor Jančuljak, et al.
Published: (2024-01-01)

Fremanezumab in real-life clinical practice: specialized headache center experience
by: Yu. E. Azimova, et al.
Published: (2024-06-01)

Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study
by: Varnado OJ, et al.
Published: (2024-01-01)

Anti-CGRP monoclonal antibodies in the treatment of migraine in women: impact on menstrual relared migraine and algodysmenorrhea
by: Anna V. Berdnikova, et al.
Published: (2023-10-01)

Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials
by: Saigoh K, et al.
Published: (2023-05-01)

Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials
by: Saigoh K, et al.
Published: (2023-04-01)

Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence
by: Bianca Orlando, et al.
Published: (2024-09-01)

Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far?
by: Theodoros Mavridis, et al.
Published: (2021-07-01)

A case report of a chronic migraine patient treated with three different anti-CGRP monoclonal antibodies: which parameters better represent the efficacy?
by: Sena Uzun, et al.
Published: (2023-05-01)

Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study
by: Licia Grazzi, et al.
Published: (2024-02-01)

Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan
by: Shiho Suzuki, et al.
Published: (2023-07-01)

GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures
by: Piero Barbanti, et al.
Published: (2025-05-01)

Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
by: Root S, et al.
Published: (2023-02-01)

Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
by: Noboru Imai, et al.
Published: (2023-09-01)

Scaling Approaches for Pediatric Dose Selection: The Fremanezumab (AJOVY<sup>®</sup>) Journey to Select a Phase 3 Dose Using Pharmacokinetic Data from a Phase 1 Study
by: Aksana Jones, et al.
Published: (2021-05-01)

Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients with Migraine: Three Cases
by: Kenta Kashiwagi, et al.
Published: (2023-02-01)

A real-world study of the efficacy and tolerability of fremanezumab in migraine patients with a median follow-up of 14 months
by: Shiho Suzuki, et al.
Published: (2025-06-01)

Real-world efficacy and tolerability of fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, observational study
by: Christopher Kjaer Cullum, et al.
Published: (2023-08-01)

Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study
by: Danilo Antonio Montisano, et al.
Published: (2024-04-01)

Semi-Automated Recording of Facial Sensitivity in Rat Demonstrates Antinociceptive Effects of the Anti-CGRP Antibody Fremanezumab
by: Nicola Benedicter, et al.
Published: (2023-04-01)

Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
by: Piero Barbanti, et al.
Published: (2024-08-01)

Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review
by: Altamura C, et al.
Published: (2023-11-01)

Reversion of chronic to episodic migraine in working age and botulinum toxin‐resistant patients treated with fremanezumab: A real‐life study
by: Juan Tudela‐Tomas, et al.
Published: (2024-07-01)

A retrospective analysis of migraine prophylaxis with anti-CGRP monoclonal antibodies at the hospital of Lithuanian University of Health Sciences Kaunas Clinics
by: V. Karpavičiūtė, et al.
Published: (2023-10-01)